MedTech Dive April 9, 2024
Sensitivity for the multi-cancer early detection test rose to almost 64% in the six cancers with the shortest five-year survival rate.
Dive Brief:
- Exact Sciences’ multi-cancer early detection (MCED) blood test has achieved 50.9% sensitivity at 98.5% specificity across 21 cancer types, the company said Monday at the American Association for Cancer Research’s annual meeting in San Diego.
- Sensitivity rose to 63.7% in the six cancer types with the shortest five-year survival rate, including lung, ovary and pancreas. Leerink Partners analysts said the results “appear promising” in a note to investors, adding that the test could be more cost-effective than sequencing-based products such as Grail’s Galleri.
- A registrational clinical trial could be the next step but Exact has scaled...
Today's Sponsors
Today's Sponsor